ClinicalTrials.gg
CompletedNCT04951700Updated Oct 30, 2026

Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia

An observational study in Schizophrenia, Aging and Disease Course, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by University of Texas Southwestern Medical Center · Observational

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
194
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Schizophrenia by University of Texas Southwestern Medical Center — 2 open to participants now, 2 under way, none of them phase 3. Schizophrenia · University of Texas Southwestern Medical Center.

Started
2021
the only one that year
Observational
4 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Schizophrenia by University of Texas Southwestern Medical Center, this one is the only one that started in 2021, is one of 4 observational ones, and was the 10th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 10 studies in Schizophrenia by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Schizophrenia by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

The 2020 NIMH Strategic Plan for Research calls for investigations targeting neurobiology of mental illness across the lifespan. Growing evidence suggests that lifespan neurobiology of schizophrenia (SZ) incorporates two distinct dimensions: aging and disease course. However, their clinical correlates, associated biomarker trajectories, and implications for treatment are unknown. This study will investigate differential aspects of SZ neurobiology captured by aging and disease course, in order to develop specific biomarkers which may offer actionable targets for SZ stage-dependent intervention. The study is predicated on a novel mechanistic Model of SZ Trajectories across the Adult Lifespan, positing distinct biological fingerprints within the anterior limbic system for aging and disease course in SZ: (1) alterations in the circuit's function and structure that occur earlier in the lifespan and are larger in magnitude than the alterations expected with normal aging (accelerated aging dimension); and (2) regionally-specific anterior limbic "hyperactivity" in early SZ, with a subsequent transformation into "hypoactivity" in advanced SZ (disease course dimension). In a sample of SZ and matched healthy controls (n=168, 84/group) aged 18-75 years the investigators will ascertain a broad panel of biomarkers [via multimodal brain imaging: optimized 1H-MRS, high-resolution task-based fMRI, perfusion (Vascular Space Occupancy) and structural MRI], along with comprehensive cognitive and clinical assessments. All measures will be acquired at baseline and repeated at 2-year longitudinal follow-up. Using cutting-edge computational approaches, the study will examine (i) effects of aging and SZ course on anterior limbic system biomarkers; (ii) lifespan trajectories for different biomarkers; (iii) patterns of limbic system biomarkers in age- and SZ course-based subgroups (e.g., Younger vs. Older, Early-Course vs. Advanced SZ), as well as in data-driven subgroups (e.g., those with vs. without accelerated aging profiles); and (iv) associations between biomarkers and cognitive and clinical outcomes. This research will advance the field by providing novel biomarkers that capture unique neurobiological contributions of aging and disease course in SZ, and will motivate future studies on SZ mechanisms across the lifespan and development of precision treatments.

Read the detailed description

Specific Aims: In order to investigate aging and disease course dimensions in SZ, the study will ascertain a broad panel of biomarkers using multimodal brain imaging, along with comprehensive cognitive and clinical measures, which will allow integration of in vivo molecular; circuit structure and function; and clinical levels of system pathology.

Aim 1. In vivo Molecular Biomarkers. Examine age- and disease course-dependent effects on excitatory and inhibitory 1H-MRS-based biomarkers in the anterior limbic system in SZ. SZ and CON (n=84/group) will undergo novel triple-refocusing 1H-MRS with Glutamate (Glu), GABA and broader metabolite measures from bilateral Hipp and mPFC. Hypothesis 1.1: SZ will show declines in Hipp-mPFC Glu and GABA along the lifespan, with significantly earlier and larger reductions than those observed in CON. Hypothesis 1.2: SZ will show distinct Hipp-mPFC Glu and GABA markers along the disease course, with significantly elevated or equivalent Glu, and reduced GABA levels, in early SZ, and reduced Glu and GABA in advanced SZ, compared to CON.

Aim 2. Functional Circuit Biomarkers. Examine age- and disease course-dependent effects on intrinsic and task-based activation biomarkers in the anterior limbic circuit in SZ, using high resolution perfusion [Vascular Space Occupancy] and functional MRI with an episodic memory [Pattern Separation] task, respectively. Hypothesis 2.1: SZ will show declines in Hipp-mPFC intrinsic and task-based activity along the lifespan, with significantly earlier and larger reductions than those in CON. Hypothesis 2.2: SZ will show distinct Hipp-mPFC intrinsic and task-dependent activity signatures across the disease course, with significantly elevated or equivalent regional activation in early SZ, and reduced activation in advanced SZ, compared to CON.

Aim 3. Structural Circuit Biomarkers. Examine age- and disease course-dependent effects on structural biomarkers in the anterior limbic system in SZ, using high resolution structural MRI. Hypothesis 3.1: SZ will show declines in cortical thickness and volume in Hipp, mPFC and broader fronto-temporal regions across the lifespan, with significantly earlier and larger reductions than those in CON. Hypothesis 3.2: SZ will show distinct fronto-temporal alterations along the disease course, with modestly reduced cortical thickness and volume measures in early SZ and larger reductions in advanced SZ, compared to CON.

The investigators also predict that molecular, functional, and structural alterations in the anterior limbic system will be associated with impaired episodic memory and broader cognitive dysfunction in SZ, with declining cognition along both the lifespan and SZ course.

This research will advance the field by providing novel biomarkers that capture unique neurobiological contributions of aging and disease course in SZ, and will motivate future studies on SZ mechanisms across the lifespan, and the development of relevant precision treatments.

03

Conditions studied

  • Schizophrenia
  • Aging
  • Disease Course
  • Biomarker
  • Neuroimaging
  • Cognitive Dysfunction
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Study population will include individuals with psychotic disorders (schizophrenia or schizoaffective disorder) and healthy comparison participants (individuals without personal history of lifetime psychiatric disorders, or a family history of psychotic disorders in 1st- or 2nd-degree relatives). Participants will be women and men, all races and ethnicities. Participants with schizophrenia/schizoaffective disorder will be aged 18-65 years, healthy comparison participants will be aged 18-75 years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years of age (SZ); 18-75 years of age (CON)
  • Women and men
  • All races and ethnicities
  • Psychiatric diagnoses:

Patient participants (SZ): Meet criteria for schizophrenia or schizoaffective disorder Healthy control participants (CON): No personal history of lifetime psychiatric disorders, or a family history of psychotic disorders in 1st-or 2nd- degree relatives

  • Able to read, speak, and understand English
  • Able and willing to provide written ; and willing to commit to the study protocol, including 2-year longitudinal follow-up

Exclusion criteria

Exclusion Criteria:

  • Compromised cognitive function: Both SZ and CON participants: Estimated premorbid intellectual ability \<75 age-corrected score on Wide Range Achievement Test-4/Word Reading Subtest (WRAT-4) CON participants: \<26 score on the (MoCA)
  • Neurological or medical disorder that may affect brain function (history of stroke, head injury with a loss of consciousness >10 min, seizure disorder, AIDS, poorly controlled hypertension, poorly controlled diabetes, decompensated lung disease, etc.)
  • Co-morbid diagnosis of drug/alcohol use disorder in prior 3 months
  • Current treatment with benzodiazepine or non-benzodiazepine sedatives/hypnotics, and/or anticonvulsants
  • Presence of ferromagnetic objects in body
  • Weight or body size exceeding MRI scanner capacity [>300 lbs]
  • Claustrophobia in MRI scanner
  • Pregnant women
  • Breastfeeding women (VASO scan will not be administered. All other imaging modalities are safe to administer.)
  • Impaired kidney function: (GFR) \< 30 ml/min/1.73m2 (VASO scan will not be administered due to an association between Gadolinium-based MR contrast use and Nephrogenic Systemic Fibrosis in individuals with severely impaired renal function. All other imaging modalities are safe to administer.)
  • History of to any MRI contrast agent (VASO scan will not be administered. All other imaging modalities are safe to administer.)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
194 participants (actual)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Schizophrenia

    Women and men, all races and ethnicities, aged 18-65 years, meeting diagnostic DSM-5 criteria for schizophrenia or schizoaffective disorder.

    Other: Other

  • Healthy Controls

    Women and men, all races and ethnicities, aged 18-75 years, without personal history of lifetime psychiatric disorders, or a family history of psychotic disorders in 1st- or 2nd-degree relatives.

    Other: Other

Interventions

  • OtherOther

    This is not an intervention study

06

What researchers measure

Primary outcomes

  1. Effects of aging and disease course on excitatory and inhibitory biomarkers in the anterior limbic system in schizophrenia (SZ) and healthy controls (CON) (Aim1 Outcomes).

    SZ and CON (n=84/group) will undergo novel triple-refocusing Magnetic Resonance Spectroscopy (1H-MRS) with Glutamate, GABA and broader metabolite measures from the anterior limbic system structures (bilateral hippocampi (Hipp) and medial prefrontal cortex (mPFC)), at baseline and 2-year longitudinal follow-up. Hypothesis 1.1: SZ will show declines in Glutamate and GABA in the Hipp and mPFC along the lifespan, with significantly earlier and larger reductions than those observed in CON. Hypothesis 1.2: SZ will show distinct Hipp-mPFC Glutamate and GABA markers along the disease course, with significantly elevated or equivalent Glutamate, and reduced GABA levels, in early SZ, and reduced Glutamate and GABA in advanced SZ, compared to CON.

    Time frame: 2 years

  2. Effects of aging and disease course on intrinsic activity biomarkers [VASO-based Cerebral Blood Volume (CBV)] in the anterior limbic circuit in SZ and CON (Aim2 Outcome).

    SZ and CON will undergo high-resolution brain perfusion imaging (VASO) at baseline and 2-year longitudinal follow-up. Hypothesis 2.1: SZ will show declines in Hipp-mPFC CBV along the lifespan, with significantly earlier and larger reductions than those observed in CON. Hypothesis 2.2: SZ will show distinct Hipp-mPFC CBV signatures across the disease course, with significantly elevated or equivalent CBV in early SZ, and reduced CBV in advanced SZ, compared to CON.

    Time frame: 2 years

  3. Effects of aging and disease course on memory task-driven activation biomarkers [fMRI with Pattern Separation task] in the anterior limbic circuit in SZ and CON (Aim2 Outcome).

    SZ and CON will undergo high-resolution brain fMRI with associational memory (Pattern Separation) task at baseline and 2-year longitudinal follow-up. Hypothesis 2.1: SZ will show declines in regional activation (BOLD signal) with Lure\>Repetition contrast along the lifespan, with significantly earlier and larger reductions than those in CON. Hypothesis 2.2: Within the disease course dimension, early SZ will show increased activation with a loss of activation modulation (e.g., increased BOLD signal with both Lures and Repetitions), with a subsequent decline in activation in mid-course and advanced SZ, compared to CON. We predict that these activation effects will be preset in the Hipp DG/CA3 and in a broader circuit supporting pattern separation operations (i.e., mPFC, parahippocampal, retrosplenial cortex).

    Time frame: 2 years

  4. Effects of aging and disease course on cortical thickness biomarkers in the anterior limbic system in SZ and CON (Aim3 Outcomes).

    SZ and CON will undergo high-resolution structural brain MRI, at baseline and 2-year longitudinal follow-up. Hypothesis 3.1: SZ will show declines in FreeSurfer-based cortical thickness in Hipp, mPFC and broader fronto-temporal regions across the lifespan, with significantly earlier and larger reductions than those in CON. Hypothesis 3.2: SZ will show distinct fronto-temporal alterations along the disease course, with modestly reduced cortical thickness in early SZ and larger reductions in advanced SZ, compared to CON.

    Time frame: 2 years

  5. Effects of aging and disease course on gray matter volume biomarkers in the anterior limbic system in SZ and CON (Aim3 Outcomes).

    SZ and CON will undergo high-resolution structural brain MRI, at baseline and 2-year longitudinal follow-up. Hypothesis 3.1: SZ will show declines in gray matter volumes (measured with FreeSurfer and Voxel-Based Morphometry) in Hipp, mPFC and broader fronto-temporal regions across the lifespan, with significantly earlier and larger reductions than those in CON. Hypothesis 3.2: SZ will show distinct fronto-temporal alterations along the disease course, with modestly reduced gray matter volume in early SZ and larger reductions in advanced SZ, compared to CON.

    Time frame: 2 years

Other outcomes

  1. Associations between brain MRI and cognitive and clinical measures.

    A broad panel of cognitive (Wide Range Achievement Test/Reading Subtest (WRAT-4/Reading Subtest), Brief Assessment of Cognition in Schizophrenia (BACS), California Verbal Learning Test-2nd Edition (CVLT-II), Ruff-Light Trial Learning Test (RULIT)) and clinical (socio-demographic information, psychiatric, medical and treatment history, family history, concomitant medications, Structured Clinical Interview for DSM-5 (SCID-5), Global Assessment of Functioning (GAF), Birchwood Social Functioning Scale (SFS), Positive and Negative Syndrome Scale PANSS), Lifetime Dimensions of Psychosis Scale (LDPS), Ciompi's Observed Course Chart, Fagerstrom Test for Nicotine Dependence) assessments will be collected from SZ and CON, at baseline and 2-year longitudinal follow-up. Associations between multimodal brain MRI measures and cognitive and clinical measures will be examined.

    Time frame: 2 years

07

Study locations

1 site
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in May 2026, 58 months.

Of 114 non-industry observational studies under Schizophrenia, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 114. This study's 58 months is close to that.

Counting every sponsor, half of 136 studies reached it within 47 months; a quarter within 27 and three quarters within 102.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Apr 2026 → May 2026 and completion Apr 2027 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2021
First posted
Jul 7, 2021
StartActual
Jul 1, 2021
Primary completionActual
May 28, 2026was Apr 2026
CompletionActual
May 28, 2026was Apr 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Primary completion
Apr 30, 2026→May 28, 2026 (actual)
Oct 30, 2026
Study completion
Apr 30, 2027→May 28, 2026 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    Primary completion Apr 30, 2026→May 28, 2026 (now actual)
    Study completion Apr 30, 2027→May 28, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04951700
Responsible party
Elena Ivleva (ASSOC PROFESSOR, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jul 7, 2021
Start date
Jul 1, 2021
Primary completion
May 28, 2026
Completion
May 28, 2026
Last update
Oct 30, 2026

Study contacts

Elena I. Ivleva, MD, PhD
principal investigator · UT Southwestern Medical Center, Department of Psychiatry

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion